Aandeel CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Creative Medical Technology Holdings, Inc.

Aandelen

CELZ

US22529Y4089

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 26-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
4,32 USD -1,82% Intraday-grafiek van Creative Medical Technology Holdings, Inc. -10,19% -6,29%
22/03 Creative Medical Technology Holdings, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023 CI
07/03 Creative Medical Technology Holdings Inc. Kondigt FDA-goedkeuring aan voor Type 1 Diabetes Preventie Therapie onder Uitgebreide Toegang CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Creative Medical Technology Holdings Provides Corporate Update
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures
Creative Medical Shares Rally Premarket on FDA Orphan Designation
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony
Top Premarket Gainers
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem
Creative Medical Technology Holdings Provides Corporate Update
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem Novel Cell Therapy to Treat Chronic Lower Back Pain
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine using AlloStem for the Treatment of Chronic Lower Back Pain
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers CELZ
  4. Nieuws Creative Medical Technology Holdings, Inc.
  5. Andere talen